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ExtEndEd rEport
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AbstrACt
Objectives to analyse the impact of tumour necrosis 
factor inhibitors (tnFis) on spinal radiographic 
progression in ankylosing spondylitis (AS).
Methods patients with AS in the Swiss Clinical Quality 
Management cohort with up to 10 years of follow-
up and radiographic assessments every 2 years were 
included. radiographs were scored by two readers 
according to the modified Stoke Ankylosing Spondylitis 
Spine Score (mSASSS) with known chronology. 
the relationship between tnFi use before a 2-year 
radiographic interval and progression within the interval 
was investigated using binomial generalised estimating 
equation models with adjustment for potential 
confounding and multiple imputation of missing 
values. Ankylosing Spondylitis disease Activity Score 
(ASdAS) was regarded as mediating the effect of tnFi 
on progression and added to the model in a sensitivity 
analysis.
results A total of 432 patients with AS contributed 
to data for 616 radiographic intervals. radiographic 
progression was defined as an increase in ≥2 mSASSS 
units in 2 years. Mean (Sd) mSASSS increase was 0.9 
(2.6) units in 2 years. prior use of tnFi reduced the odds 
of progression by 50% (or 0.50, 95% CI 0.28 to 0.88) 
in the multivariable analysis. While no direct effect of 
tnFi on progression was present in an analysis including 
time-varying ASdAS (or 0.61, 95% CI 0.34 to 1.08), the 
indirect effect, via a reduction in ASdAS, was statistically 
significant (or 0.75, 95% CI 0.59 to 0.97).
Conclusion tnFis are associated with a reduction of 
spinal radiographic progression in patients with AS. this 
effect seems mediated through the inhibiting effect of 
tnFi on disease activity.
IntrOduCtIOn
The introduction of tumour necrosis factor inhibi-
tors (TNFis) nearly two decades ago has considerably 
improved the treatment of ankylosing spondylitis (AS) 
in patients with insufficient response to conventional 
treatment by reducing symptoms and signs of the 
disease, together with reduced inflammatory activity 
in the sacroiliac joints and the spine.1 Besides inflam-
mation, spinal damage caused by new bone formation 
contributes to impairment of spinal mobility and func-
tion in AS.2 Therefore, retarding spinal radiographic 
progression in addition to improving symptoms 
should remain an important treatment goal.3 While 
an association between disease activity and future 
spinal radiographic progression has been demon-
strated,4 5 the deductive reasoning that lowering 
inflammation by TNFi might inhibit radiographic 
damage remains elusive. Three open-label extensions 
of randomised controlled trials of TNFi in AS over 2 
years failed to demonstrate inhibition of radiographic 
progression in comparison with a historical cohort 
of patients not treated with biologicals.6–8 However, 
TNFi use was associated with a lower odds of spinal 
radiographic progression in an observational study.9 
Methodological shortcomings of this latter publica-
tion and requirements for prospective cohort anal-
yses to elucidate this controversial issue have been 
amply discussed.10 We hereby present a longitudinal 
analysis of up to 10 years of follow-up, with 2-year 
clinical and radiographic intervals, with the aim of 
investigating the relationship between treatment with 
TNFi, subsequent course of disease activity and spinal 
radiographic progression.
MethOds
study population
We used data from the ongoing Swiss Clinical 
Quality Management (SCQM) cohort of patients 
with a clinical diagnosis of axial spondyloar-
thritis (axSpA).11 Clinical assessments, following 
the recommendations of ASAS,12 were performed 
at annual visits. Radiographs of the cervical and 
lumbar spine were recommended every 2 years. 
Patients were included in the present study if they 
fulfilled the modified New York criteria for AS13 
with central reading of the pelvic radiographs and if 
they had at least two sets of spinal radiographs with 
an interval of 2 years±1 year. Sensitivity analyses 
were performed in patients with interval duration 
between radiograph sets of 2 years±6 months. The 
study was approved by the Ethics Committee of 
the Canton of Zurich (KEK-ZH-Nr. 2014–0439). 
Written informed consent was obtained from all 
patients.
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Assessment of radiographic progression
All available radiographs per patient were scored at the same time 
according to the modified Stoke Ankylosing Spondylitis Spine 
Score14 (mSASSS) by two trained readers (XB and MdH) inde-
pendently, blinded to all other data, but with known chronology. 
Averaged scores per vertebral corner (VC) were used. An inde-
pendent adjudicator (AC) scored all of the radiographs from 
patients with an absolute difference in mSASSS status scores 
between the primary readers of ≥5 units in at least one radio-
graph set. Only scores of radiographs with ≤3 missing VCs per 
cervical or lumbar segment were used. Individual missing VCs 
were imputed using an adaptation algorithm (see online supple-
mentary materials). Radiographic progression was defined as 
an increase in mSASSS of at least 2 units over an interval of 2 
years, based on calculations of the smallest detectable change 
(SDC).15 In addition, we assessed the proportion of patients with 
formation of at least one new syndesmophyte over a period of 
2 years.16
statistical analysis
Reliability between the two readers for mSASSS was explored by 
Bland-Altman plot on 2-year progression intervals of mSASSS 
and by calculating the SDC for 2-year progression scores 
and the intraclass correlation coefficient (ICC; type 2, k) on 
mSASSS. The relationship between TNFi treatment and radio-
graphic progression over time was investigated using binomial 
generalised estimating equations (GEE) to account for repeated 
measurements within a patient. An ‘exchangeable’ correlation 
structure was chosen (see online supplementary materials). The 
duration of radiographic intervals was added as a covariate to 
the model to account for differences in interval lengths. Progres-
sion of ≥2 mSASSS units in 2 years was modelled by using the 
binomial family and the logistic link function. To account for 
missing values, the GEE was fitted using multiple imputation of 
missing covariate data (see online supplementary materials).
The GEE analyses were adjusted for baseline radiographic 
damage16 17 (mSASSS or the presence of syndesmophytes18 in 
different models), sex,19 symptom duration, human leuco-
cyte antigen B27 (HLA-B27) status,19 smoking status,17 20 21 
the number of physical activity sessions per week,22 presence 
of peripheral arthritis,23 body mass index categories and treat-
ment with non-steroidal anti-inflammatory drugs (NSAIDs)24 25 
recorded as a dichotomous variable (yes/no) at every visit. To 
address the issue of confounding by indication, a model was 
fitted that was additionally adjusted for the Ankylosing Spondy-
litis Disease Activity Score (ASDAS) value before start of TNFi 
(ASDAS at inclusion for non-TNFi patients).
Based on available data on the potential impact of TNFi on 
progression to date,6–9 26 27 different longitudinal models were 
run that varied with regards to the variable representing TNFi 
treatment: use of TNFi prior to the radiographic interval as yes/
no, as number of years of continuous use of TNFi, or alterna-
tively, as ≤4 years versus >4 years of TNFi use,9 26 27 treatment 
with TNFi during the 2 year radiographic interval as yes/no or 
as duration of use of <50% versus ≥50% of the radiographic 
interval.
Disease activity variables (Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI) and C reactive protein (CRP) 
or ASDAS) after start of TNFi were regarded as potential inter-
mediate variables mediating the effect of TNFi on radiographic 
progression and were therefore not included in the main statis-
tical models. To investigate the potential mediating effect of 
disease activity on the impact of TNFi (independent variable) on 
radiographic progression (dependent variable), we estimated the 
indirect effect and tested it with the Sobel test with second-order 
estimator of the SE, as described by Hayes.28 The direct effect 
of TNFi on radiographic progression was tested by introducing 
disease activity variables (BASDAI, CRP or ASDAS) at start of 
each radiographic interval in the main models.
results
A total of 432 patients with AS presented with at least one 2-year 
radiographic interval during the observation period in SCQM. 
Mean (SD) time between radiographs was 2.1 (0.4) years. 
Interobserver reliability was ‘good’ (ICC 0.85). The SDC of 
progression in a 2-year radiographic interval was 1.89 mSASSS 
units, which is below the threshold of 2 mSASSS units defining 
progression. A Bland-Altman plot is shown in the online supple-
mentary figure S1. Adjudication was performed in 130 patients. 
Baseline disease characteristics are shown in table 1.
table 1 Baseline characteristics at first radiograph
Parameter n
Male sex, % 432 65.7
HLA-B27 positive, % 391 80.6
Age, years 432 40.3 (11.0)
Symptom duration, years 424 13.8 (9.7)
BASDAI 369 4.2 (2.3)
ASDAS 351 2.8 (1.1)
CRP (mg/L), median (IQR) 365 8.0 (3.0; 11.0)
Elevated CRP, % 364 40.4
BASFI 373 3.1 (2.6)
BASMI 375 2.2 (2.0)
mSASSS, median (IQR) 432 1.0 (0.0; 6.0)
mean (SD) 6.6 (12.5)
Syndesmophytes present, % 432 34.3
EQ-5D 370 65.1 (21.6)
Current peripheral arthritis, % 378 28.6
Current enthesitis, % 381 54.3
BMI 25–30, % 373 29.5
BMI >30, % 373 15.6
On NSAID treatment, % 341 83.9
On TNFi treatment, % 432 37.7
Ever TNFi treatment, % 432 43.1
Years of TNFi treatment in treated patients 163 2.1 (1.7)
Current smokers, % 365 38.4
Number exercise sessions per week, median 
(IQR)
366 2.0 (0.0; 2.0)
Patients with different number of radiographic 
intervals*, %
432 100
  One interval 304 70.4
  Two intervals 83 19.2
  Three intervals 35 8.1
  Four intervals 9 2.1
  Five intervals 1 0.2
Except where indicated otherwise, values are the mean (SD).
*Differences in baseline characteristics in patients with different number of 
radiographic intervals are provided in the online supplementary table S8.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional 
Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BMI, body mass index; 
CRP, C reactive protein; EQ-5D, EuroQol 5-domain; HLA-B27, human leucocyte 
antigen B27; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; NSAID, 
non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor.
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Adjusted longitudinal analyses
Mean (SD) radiographic progression was 0.9 (2.3) mSASSS units 
in 2 years. Any TNFi use before a radiographic interval (yes vs 
no) was used as main TNFi variable in the adjusted analyses 
(figure 1A). Prior TNFi treatment versus no TNFi treatment 
was associated in multivariable analyses of 616 radiographic 
intervals in 432 patients with a reduction of the odds for radio-
graphic progression during the next 2-year interval by 50% (OR 
0.50, 95% CI 0.28 to 0.88, p=0.02). Baseline mSASSS (OR 
1.06, 95% CI 1.04 to 1.09, p<0.001) and male sex (OR 2.16, 
95% CI 1.09 to 4.30, p=0.03) were associated with an increase 
in radiographic damage after 2 years. The impact of prior TNFi 
use in reducing radiographic progression during the next 2-year 
radiographic interval was confirmed in an adjusted model with 
progression defined as the appearance of at least one new syndes-
mophyte in 2 years (OR 0.55, 95% CI 0.33 to 0.94) (figure 1B). 
Treatment with NSAIDs at baseline, smoking, HLA-B27, periph-
eral arthritis, overweight, obesity and physical exercise were not 
found to be associated with an effect on radiographic progres-
sion in both models. The estimated impact of prior TNFi use 
was not affected by the additional adjustment for disease activity 
measures (ASDAS) before treatment start, performed to address 
the issue of confounding by indication (table 2).
The magnitude of the effect of all variables on progression 
was also confirmed in the subset of patients with radiographic 
interval duration of 2 years±6 months and in a complete case 
analysis of 403 radiographic intervals from 301 patients (see 
online supplementary tables S1 and S2, respectively).
A beneficial effect of TNFi treatment before a radiographic 
interval on progression was also confirmed in adjusted models 
with alternative variable choices for TNFi use, as summarised in 
table 3 and presented in full in the online supplementary tables 
S3 and S4. These data also suggest that a longer duration of 
TNFi treatment is associated with a stronger protective effect, 
since each additional year of continuous TNFi therapy before 
a radiographic interval was associated with a reduced risk of 
progression (model 2 in table 3). Moreover, >4 years of treat-
ment before the radiographic interval resulted in a lower estimate 
of progression than ≤4 years of TNFi use (model 3 in table 3). 
In contrast to prior TNFi use, TNFi treatment during a 2-year 
radiographic interval (assessed either as ‘yes/no’ or as ‘duration 
of TNFi treatment during the interval (≤50% vs >50%)’) was 
not associated with a reduction of progression in the respective 
interval (models 4 and 5 in table 3 and  online supplementary 
tables S5 and S6).
Impact of reduction of disease activity by tnFi on 
radiographic progression
TNFi treatment before a 2-year radiographic interval was asso-
ciated with a reduced disease activity at the start of that interval, 
as assessed by the ASDAS: −0.96 units, 95% CI −1.15 to −0.77, 
p<0.001. The association of disease activity measures at baseline 
of a 2-year radiographic interval with progression in the respec-
tive interval was analysed in separate GEE models with base-
line mSASSS as dependent variable (models 6–8 in table 4). A 
higher ASDAS increased the probability of radiographic progres-
sion (OR 1.39, 95% CI 1.06 to 1.81). When adding ASDAS as 
a covariate to the multivariable model displayed in figure 1A, 
it was significantly associated with radiographic progression 
Figure 1 Multivariable analysis of 616 radiographic intervals from 432 patients after multiple imputation of missing covariate data for the 
identification of factors associated with (A) radiographic progression defined as an increase of ≥2 mSASSS units per 2 years and (B) radiographic 
progression defined as the formation of at least one new syndesmophyte per 2 years. Analysis performed in 616 radiographic intervals from 432 
patients after multiple imputation of missing covariate data. BMI, body mass index; HLA-B27, human leucocyte antigen B27; mSASSS, modified Stoke 
Ankylosing Spondylitis Spine Score; NSAIDs, non-steroidal anti-inflammatory drugs; Ref, reference; TNFi, tumour necrosis factor inhibitor. *mSASSS at 
start of each 2-year radiographic interval in A and presence of syndesmophytes at start of each 2-year radiographic interval (yes vs no) in B.
66 Molnar C, et al. Ann Rheum Dis 2018;77:63–69. doi:10.1136/annrheumdis-2017-211544
Clinical and epidemiological research
(table 4, model 9). The TNFi variable in the model without 
ASDAS captures the total TNFi effect on progression. In a 
model with ASDAS, the TNFi variable coefficient estimated the 
direct effect of TNFi on radiographic progression, which was 
not significant (OR 0.61, 95% CI 0.34 to 1.08, p=0.09). The 
estimated indirect effect of TNFi on progression via a reduction 
in ASDAS was on the contrary statistically significant (OR 0.75, 
95% CI 0.59 to 0.97, p=0.01).
When analysing the unadjusted radiographic progression 
in 2-year intervals following the use of TNFi, responders to 
TNFi (defined by an ASDAS ≤2.1 at start of the radiographic 
interval) had a significantly lower mean spinal progression than 
non-responders to TNFi (defined by ASDAS >2.1), with a mean 
mSASSS progression of 0.31 versus 1.45 units (Kruskal-Wallis 
test p=0.02). Radiographic progression was entirely inhibited in 
TNFi patients reaching an inactive disease status (ASDAS ≤1.3) 
at the start of the next 2-year radiographic interval (mean spinal 
progression in these patients was 0.01 mSASSS units vs 0.52 
mSASSS units in patients with ASDAS between 1.3 and 2.1, Krus-
kal-Wallis test p=0.01). Cumulative probability plots of spinal 
progression after stratification by ASDAS status at the start of the 
next radiographic interval are presented for patients treated with 
TNFi in figure 2. Stratification by baseline CRP status (elevated 
CRP vs normal CRP) segregated less well between radiographic 
progressors and non-progressors in this population than stratifi-
cation by the ASDAS (see online supplementary figure S2).
dIsCussIOn
The current longitudinal analysis of a large observational 
national cohort, consisting of both patients treated with TNFi 
and untreated patients, supports the notion of an effect of TNFi 
treatment on inhibition of radiographic spinal progression in 
patients with AS. As residual confounding cannot be completely 
ruled out in an observational context, causality could not be 
proven, although it remains the most plausible explanation for 
our findings. Long-term randomised controlled trials to defin-
itively clarify this issue will never be performed for ethical 
reasons.
We demonstrate an association between TNFi use and reduced 
risk of spinal structural damage, both in terms of mSASSS and 
new syndesmophyte formation. The odds of radiographic 
progression were nearly halved over the next 2 years in patients 
having started TNFi treatment before this 2-year interval. The 
pattern of correlations demonstrated in our mediational anal-
yses is consistent with the hypothesis that the impact of TNFi 
table 2 Impact of pretreatment Ankylosing Spondylitis Disease Activity Score (ASDAS) on spinal radiographic progression
Variable Or 95% CI p Value
TNFi use before radiographic interval yes/no 0.52 0.29 to 0.92 0.02
AsdAs at start of TNFi and ASDAS at inclusion for non-treated patients 1.33 1.00 to 1.78 0.05
mSASSS at start of each radiographic interval 1.07 1.04 to 1.09 <0.001
Male sex 2.10 1.07 to 4.12 0.03
Disease duration (5 years) 1.13 0.99 to 1.29 0.07
Current smoking 1.04 0.59 to 1.86 0.88
HLA-B27 1.03 0.46 to 2.29 0.94
Number of exercise sessions per week 0.95 0.82 to 1.10 0.47
Peripheral arthritis 0.87 0.48 to 1.60 0.66
NSAID use at start of each radiographic interval 0.83 0.41 to 1.68 0.60
BMI 25–30 (Reference: BMI <25) 1.39 0.77 to 2.49 0.27
BMI >30 (Reference: BMI <25) 1.66 0.81 to 3.39 0.16
Duration of radiographic interval 1.66 0.85 to 3.23 0.14
Radiographic spinal progression defined as an increase in mSASSS ≥2 units. The model corresponds to the multivariable model used in figure 1A with the additional 
incorporation of pretreatment ASDAS in TNFi-treated patients as a covariate in order to account for confounding by indication. The ASDAS at inclusion was considered for non-
TNFi-treated patients (616 radiographic intervals from 432 patients after multiple imputation of missing covariate data).
ASDAS, Ankylosing Spondylitis Disease Activity Score; BMI, body mass index; HLA-B27, human leucocyte antigen B27; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score; 
NSAID, non-steroidal anti-inflammatory drug; TNFi, tumour necrosis factor inhibitor.
table 3 Impact of alternative variable choices for TNFi use on spinal radiographic progression from different multivariable models*
Model Alternative variable choices for tnFi use Or 95% CI p Value
1 TNFi use prior to radiographic interval (yes versus no) 0.50 0.28 to 0.88 0.02
2 Number of years of continuous use of TNFi prior to interval† 0.79 0.66 to 0.94 0.01
3 ≤4 years of TNFi use prior to radiographic interval 0.55 0.31 to 0.98 0.04
>4 years of TNFi use prior to radiographic interval 0.30 0.10 to 0.90 0.03
4 TNFi use prior to radiographic interval (yes versus no) 0.52 0.27 to 0.98 0.05
TNFi use during the radiographic interval (yes versus no) 0.87 0.49 to 1.56 0.64
5 TNFi use prior to radiographic interval (yes versus no) 0.54 0.28 to 1.03 0.06
TNFi use during ≤50% of duration of radiographic interval 1.41 0.66 to 3.00 0.37
TNFi use during >50% of duration of radiographic interval 0.81 0.43 to 1.50 0.50
*Summarised results from different multivariable models with same covariates used as in figure 1 with the exception of the TNFi variable(s). Full models are depicted in the 
online supplementary tables S3–S6. Model 1 corresponds to the model in figure 1A. Spinal progression was defined as ≥2 mSASSS units in a 2-year interval. Analyses performed 
in 616 radiographic intervals from 432 patients after multiple imputation of missing covariate data.
†Estimated effect of TNFi per year of continuous TNFi use.
TNFi, tumour necrosis factor inhibitor.
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on spinal radiographic progression is mediated by its decreasing 
effect on disease activity (ASDAS, BASDAI or CRP). Only a 
trend for a direct effect of TNFi on reduction of spinal progres-
sion could be found. ASDAS outperformed BASDAI and CRP 
alone for the association of disease activity with radiographic 
progression, confirming previous analyses.4
We present important clues concerning the period of time 
needed before the inhibitory effects can be objectified: around 2 
years of continuous TNFi use, as there was no impact of TNFi 
treatment during a 2-year radiographic interval, while there 
was an effect if the treatment was started before this interval. 
Our study therefore reconciles conflicting results of previous 
investigations. Treatment with TNFi over 2 years in three open-
label extensions of randomised control trials in AS failed to 
demonstrate an inhibition of radiographic progression during 
this period.6–8 The principal explanation for this seems to be 
that inflammation needs to be suppressed for at least 2 years in 
order to demonstrate an inhibition of radiographic progression. 
In another study with fewer patients with AS, less radiographic 
progression was only demonstrated after 4 years of follow-up.26 
This was also demonstrated in two observational studies.9 27 
We confirm the finding that longer periods of treatment with 
TNFi translate into a stronger inhibition of progression in two 
different models: one accounting for the number of years of 
continuous TNFi therapy and the second using a cut-off of 4 
years of treatment.
Radiographic spinal progression was nearly entirely inhibited 
in the following 2-year radiographic interval in patients with AS 
reaching an inactive disease status (ASDAS ≤1.3)29on treatment 
with TNFi. While a treat-to-target approach has been recom-
mended, the content of the target was not mentioned.30 Our 
study suggests that ASDAS ≤1.3 might be an adequate target, if 
the goal of treatment is inhibition of further spinal radiographic 
damage in addition to control of signs and symptoms, provided 
that the target seems realistic based on the clinical context.
The issue of whether NSAIDs alone may have an impact on 
structural damage remains controversial. Continuous versus on 
demand use of celecoxib has been shown to inhibit progression 
in a randomised controlled trial, particularly in the subgroup of 
patients with elevated CRP levels.24 31 However, in a more recent 
study with similar design, diclofenac had no impact on progres-
sion.32 Conflicting results have also been found in observational 
studies.9 25 In our study, use of NSAIDs was not associated 
with an independent effect on progression. We acknowledge, 
however, that data collection in SCQM does not allow for calcu-
lation of the recommended NSAIDs index.33 We confirm in our 
study that baseline structural damage and male sex are the major 
drivers of radiographic progression.16–19
We have not addressed the issue of whether any particular 
TNFi agent might have a greater impact on spinal radiographic 
progression than another, due to insufficient patient numbers. 
The fact that the impact of TNFi on progression seems to be 
mediated by a decrease in disease activity would argue against 
major differences between individual TNFi. It also remains to be 
demonstrated whether new biological agents and in particular 
anti-interleukin-17 drugs34 also have an impact on radiographic 
progression.
Strengths of our investigation include the prospective study 
design, standardised regular clinical and radiographic assess-
ments at 2-year intervals allowing for the implementation of a 
longitudinal analysis and statistical methods (GEE analyses) that 
take into account potential confounders and the within-patient 
correlation of structural damage. We acknowledge the fact that 
our analyses were based on only one radiographic interval in 
around 2/3 of patients. The scoring of radiographs with knowl-
edge of chronology might be seen as an additional limitation, but 
it has been shown to be more sensitive to change than reading 
with paired time order,35 and readers were blinded to clinical 
data, including treatment.
In addition to the possibility of residual confounding, which 
has already been highlighted, observational studies might be 
prone to other risks of bias. We have addressed the issue of 
confounding by indication by performing sensitivity analyses 
with adjustment for disease activity measures and other covari-
ates before the start of treatment. Involvement of a multitude 
of rheumatologists throughout Switzerland in this real-life 
cohort might be the source of inconsistent data collection and 
measurement errors. We have previously demonstrated that 
adherence to ASAS treatment recommendations and response 
rates to TNFi were similar in private practices and academic 
centres.36 Classification as AS was established by central reading 
of the pelvis radiographs. We have used multiple imputation 
techniques for missing values and have provided complete case 
analyses to allow for the evaluation of the robustness of our 
investigation.
In conclusion, our data suggest that TNFi therapy in AS has 
a clinically relevant inhibitory effect on spinal radiographic 
Figure 2 Cumulative probability plot of 2-year progression in the 
modified Stoke Ankylosing Spine Score (mSASSS), illustrating the change 
in mSASSS values from baseline of each individual radiographic interval 
to 2 years in patients already treated with TNFi at start of the respective 
interval, stratified by the ASDAS cut-off level reached at the beginning 
of each radiographic interval: ASDAS >2.1 (n=111, 136 radiographic 
intervals), ASDAS >1.3 and ≤2.1 (n=68, 85 radiographic intervals) and 
ASDAS ≤1.3 (inactive disease status; n=40, 48 radiographic intervals). 
Radiographic progression was defined as an increase in mSASSS 
of ≥2 in 2 years (dotted line). ASDAS, Ankylosing Spondylitis Disease 
Activity Score.
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progression if treatment is continued for at least 2 years and that 
this effect is mediated by a decrease in disease activity.
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